Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls aged 9-17 years
2012-003025-25Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by GSK. Primary endpoint: Antibody GMTs against HPV-16 and HPV-18 at one month post-dose 3.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on 2012-003025-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003025-25.